Nichols & Pratt Advisers LLP MA Acquires 8,935 Shares of Novo Nordisk A/S $NVO

Nichols & Pratt Advisers LLP MA raised its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 1.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 500,991 shares of the company’s stock after buying an additional 8,935 shares during the quarter. Novo Nordisk A/S comprises approximately 1.8% of Nichols & Pratt Advisers LLP MA’s holdings, making the stock its 22nd largest position. Nichols & Pratt Advisers LLP MA’s holdings in Novo Nordisk A/S were worth $27,800,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Werba Rubin Papier Wealth Management increased its position in Novo Nordisk A/S by 4.1% during the second quarter. Werba Rubin Papier Wealth Management now owns 4,378 shares of the company’s stock valued at $302,000 after acquiring an additional 173 shares during the last quarter. Beacon Financial Group boosted its stake in shares of Novo Nordisk A/S by 4.3% during the third quarter. Beacon Financial Group now owns 4,307 shares of the company’s stock valued at $239,000 after purchasing an additional 178 shares during the period. Revolve Wealth Partners LLC grew its holdings in shares of Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after purchasing an additional 200 shares during the last quarter. Kavar Capital Partners Group LLC increased its stake in Novo Nordisk A/S by 0.6% in the 3rd quarter. Kavar Capital Partners Group LLC now owns 32,631 shares of the company’s stock worth $1,811,000 after buying an additional 200 shares during the period. Finally, SeaBridge Investment Advisors LLC lifted its holdings in Novo Nordisk A/S by 5.7% during the 3rd quarter. SeaBridge Investment Advisors LLC now owns 3,735 shares of the company’s stock valued at $207,000 after buying an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently commented on NVO shares. HSBC reissued a “hold” rating and issued a $54.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, December 10th. Hsbc Global Res downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. Weiss Ratings restated a “sell (d+)” rating on shares of Novo Nordisk A/S in a report on Monday, December 29th. Citigroup started coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 27th. They issued a “neutral” rating on the stock. Finally, Jefferies Financial Group began coverage on Novo Nordisk A/S in a report on Monday, October 27th. They set an “underperform” rating for the company. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Hold” and a consensus price target of $57.79.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $59.01 on Tuesday. Novo Nordisk A/S has a fifty-two week low of $43.08 and a fifty-two week high of $93.80. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78. The company has a market capitalization of $263.46 billion, a P/E ratio of 17.15 and a beta of 0.66. The business’s 50-day moving average is $53.72 and its two-hundred day moving average is $54.28.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.The company had revenue of $11.79 billion during the quarter, compared to analysts’ expectations of $11.98 billion. Research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.